Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI plus Cetuximab vs. Bevacizumab in BRAF-mutated mCRC
NCT04034459Phase 2Active, not recruiting
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Nov 2016
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in metastatic colorectal cancer (mCRC), sponsored by Ludwig Maximilian University of Munich. Started Nov 2016; status: active, not recruiting.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04034459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04034459.